Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.

Saved in:
Bibliographic Details
Title: Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Authors: van Meerten T; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Kersten MJ; Department of Hematology, Amsterdam University Medical Center, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands., Iacoboni G; Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain., Hess G; Department of Hematology/Oncology, Johannes Gutenberg-Universität Mainz, Mainz, Germany., Mutsaers P; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., García-Sancho AM; Department of Hematology, Salamanca University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, University of Salamanca, Salamanca, Spain., Goy A; John Theurer Cancer Center, Hackensack, NJ., Giné E; Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain., Hill BT; Cleveland Clinic Foundation, Cleveland, OH., Weng WK; Department of Medicine, Stanford University, Stanford, CA., Reagan PM; Department of Medicine, University of Rochester Medical Center, Rochester, NY., Patel K; Swedish Cancer Institute, Seattle, WA., Galal A; Carol G. Simon Cancer Center, Morristown, NJ., Herbaux C; Department of Clinical Hematology, Hématologie Clinique, Centre Hospitalier Universitaire Montpellier, Montpellier, France., Sanderson R; Department of Haematology, King's College Hospital, London, United Kingdom., Forcade E; Department of Clinical Hematology and Cellular Therapy, Service d'Hématologie Clinique et Thérapie Cellulaire, Bordeaux, France., Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany., Houot R; Department of Hematology, Centre Hospitalier Universitaire Rennes, Université Rennes, INSERM, Établissement Français du Sang, Rennes, France., Zheng D; Kite, a Gilead company, Santa Monica, CA., Zhang W; Kite, a Gilead company, Santa Monica, CA., Kanska J; Kite, a Gilead company, Santa Monica, CA., Shen RR; Kite, a Gilead company, Santa Monica, CA., Damico Khalid R; Kite, a Gilead company, Santa Monica, CA., Kloos I; Kite, a Gilead company, Santa Monica, CA., Dreyling M; Department of Medicine III, Ludwig Maximilian University Hospital of Munich, Munich, Germany., Wang ML; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: Blood [Blood] 2026 Mar 19; Vol. 147 (12), pp. 1302-1314.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2025029734